Engineering Effector Protein Nanoclusters for Breast Cancer Therapy
Engineering Effector Protein Nanoclusters for Breast Cancer Therapy
批准号:
1105248
负责人:
Julie Champion
金额:
$30.0万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-15 至 2015-08-31
中文摘要
ID:MPS/DMR/BMAT(7623)1105248 主要研究者:冠军,朱莉·奥格:格鲁吉亚技术标题:乳腺癌治疗的工程效应蛋白纳米簇智力优势:一组选定的细菌病原体在感染过程中分泌称为效应子的蛋白质,使它们能够在敌对宿主中生存和生长。 其中一些效应物有能力干扰乳腺癌中改变的相同途径。 该提案的目标是使用这些效应蛋白作为新的乳腺癌疗法。 为了将这些蛋白质用作抗癌药物,必须用能够将生物活性蛋白质递送到乳腺癌细胞的药物递送系统取代正常的细菌递送机制。 为了实现这一目标,效应蛋白将被连接在一起,形成纳米级的簇,这些簇可以进入乳腺癌细胞,然后分解,使单个蛋白质在细胞内发挥作用。 拟议的工作将制造效应纳米簇,并评估它们恢复乳腺癌细胞正常行为的能力,例如增加凋亡细胞死亡,减少增殖,减少转移或增加对化疗药物的敏感性。 为了实现这一目标,已经建立了四个技术目标:(1)鉴定具有治疗潜力的候选效应蛋白。 (2)制造具有受控拆卸和效应蛋白释放的效应纳米簇。 (3)评估纳米团簇递送效率和对乳腺癌细胞系的治疗效果。 (4)通过测量巨噬细胞的纳米簇摄取和细胞因子活化来评估免疫潜力。 这些目标的结果将确定使用细菌蛋白作为乳腺癌药物的可行性,以及将这些分子递送到乳腺癌细胞并获得积极治疗结果的能力。 这里描述的纳米团簇是独特的组装体,其保护蛋白质并增加传统聚合物-药物纳米颗粒的递送负载。 结果是一种新型的蛋白质治疗剂,从自然界模仿,作为生物活性剂和运载工具,在一个,用于治疗乳腺癌。更广泛的影响:鉴于乳腺癌是美国妇女最常见的癌症和癌症死亡的第二大原因,许多人可以受益于效应纳米簇的发展。 这项工作验证了使用细菌蛋白质进行治疗应用的想法,并且该概念可以扩展到其他疾病的各种药物开发和交付需求。 除了预期的科学成果外,PI还计划开展各种活动,教育非工程师以及招募和留住化学工程领域的女性。 该提案将支持一名代表性不足的少数民族女研究生。 PI将积极指导这名学生,鼓励她继续从事工程职业,并为下一代潜在的女工程师树立榜样。 PI还积极参与格鲁吉亚理工学院(GT)的妇女工程项目,她将参加诸如“介绍一个女孩到工程日”之类的外联项目。“这些方案针对的是亚特兰大地区的初中和高中女生。 其目的是让他们兴奋和感兴趣的重要项目,化学工程师的工作,通过与女工程师,如PI的互动。 除了科学出版物和演讲外,这项提议的结果还将通过一个返校节癌症研究小组与GT校友分享,并在GT科学喜剧广播节目“黑匣子内部”中与所有哥伦比亚人分享。"
英文摘要
ID: MPS/DMR/BMAT(7623) 1105248 PI: Champion, Julie ORG: Georgia TechTitle: Engineering Effector Protein Nanoclusters for Breast Cancer TherapyINTELLECTUAL MERIT: A select group of bacterial pathogens secrete proteins called effectors during infection, which enable them to survive and grow in a hostile host. Some of these effectors have the capability to interfere with the same pathways that are altered in breast cancer. The goal of this proposal is to use these effector proteins as novel breast cancer therapies. In order for these proteins to be used as anticancer drugs, the normal bacterial delivery mechanisms must be replaced by a drug delivery system able to deliver biologically active protein to breast cancer cells. To achieve this, the effector proteins will be linked together into nano-sized clusters that can enter breast cancer cells and then fall apart to allow the individual proteins to act inside the cells. The proposed work will fabricate effector nanoclusters and assess their ability to restore normal behaviors in breast cancer cells, such as increased apoptotic cell death, decreased proliferation, decreased metastasis, or increased sensitivity to chemotherapeutics. Four technical objectives have been established to achieve this goal: (1) Identify candidate effector proteins with therapeutic potential. (2) Fabricate effector nanoclusters with controlled disassembly and effector protein release. (3) Assess nanocluster delivery efficiency and therapeutic effects on breast cancer cell lines. (4) Assess immunologic potential by measurement of nanocluster uptake and cytokine activation by macrophages. The results of these objectives will establish the feasibility of using bacterial proteins as breast cancer drugs and the capability to deliver these molecules to breast cancer cells with positive therapeutic outcomes. The nanoclusters described here are unique assemblies that protect proteins and increase delivery load over traditional polymer-drug nanoparticles. The result is a new type of protein therapeutic, mimicked from nature, which serves as both the bioactive agent and delivery vehicle, all in one, for the treatment of breast cancer.BROADER IMPACTS: Given that breast cancer is the most common cancer in U.S. women and the 2nd leading cause of cancer death, many people could benefit from the development of effector nanoclusters. This work validates the idea of using bacterial proteins for therapeutic applications and the concept can be expanded for a variety of drug development and delivery needs for other diseases. Beyond the anticipated scientific results, the PI has planned a variety of activities to educate non-engineers as well as to recruit and retain women in chemical engineering. This proposal will support one female under-represented minority graduate student. The PI will actively mentor this student to encourage her to continue her career in engineering and serve as a role model for the next generation of potential female engineers. The PI is also active in the Women in Engineering program at Georgia Tech (GT), and she will participate in outreach programs such as "Introduce a Girl to Engineering Day." These programs are aimed at Atlanta-area middle and high school girls. The objective is to get them excited and interested in the important projects that chemical engineers work on through interactions with women engineers such as the PI. In addition to scientific publications and presentations, results from this proposal will be shared with GT alumni through a homecoming cancer research panel and with all Atlantans on the GT science-comedy radio show "Inside the Black Box."
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering Responsive Chemical Heterogeneity in Protein Vesicles for Simultaneous Delivery of Diverse Cargoes
-
批准号:2104734
-
项目类别:Standard Grant
-
资助金额:$43.85万
-
财政年份:2021
-
负责人:Julie Champion
-
依托单位:
International Conference on Biomolecular Engineering Asia 2018
-
批准号:1821855
-
项目类别:Standard Grant
-
资助金额:$1.5万
-
财政年份:2018
-
负责人:Julie Champion
-
依托单位:
I-Corps: Nanotechnology for Boosting Vaccine Efficacy and Longevity
-
批准号:1742660
-
项目类别:Standard Grant
-
资助金额:$5.0万
-
财政年份:2017
-
负责人:Julie Champion
-
依托单位:
Protein Vesicles: Understanding Self-Assembly of Fusion Proteins into Vesicles to Engineer Structures and Biofunctional Properties
-
批准号:1709428
-
项目类别:Continuing Grant
-
资助金额:$39.36万
-
财政年份:2017
-
负责人:Julie Champion
-
依托单位:
UNS: Engineered Protein-Inorganic Self-Assembly to Control Enzyme Performance and Recovery
-
批准号:1510551
-
项目类别:Standard Grant
-
资助金额:$30.04万
-
财政年份:2015
-
负责人:Julie Champion
-
依托单位:
BRIGE: Engineering Cytokine Scavenging Nanoparticles for Immunomodulation
-
批准号:1032413
-
项目类别:Standard Grant
-
资助金额:$17.5万
-
财政年份:2010
-
负责人:Julie Champion
-
依托单位:
国内基金
海外基金
口腔癌前病损转化微环境中IL-1β介导Treg/ T Effector免疫失衡的功能及机制
-
批准号:81600878
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:吴桐
-
依托单位: